"About Jiangsu Nhwa Pharmaceutical Co. Ltd
Jiangsu Nhwa Pharmaceutical Co., Ltd., is a Chinese pharmaceutical company committed to setting new standards in CNS healthcare. Nhwa endeavors to provide innovative, high quality medicines to CNS patients with serious unmet medical needs. Nhwa offers a growing portfolio of more than 100 marketed products covering more than 6000 hospitals throughout China, including antipsychotics, anesthetics and analgesics, and neurological products. For more than 60 years, Nhwa has focused on CNS medicine, and every member of Nhwa's approximately 3,000-strong workforce is dedicated to improving patient health and outcomes."
Ich erklär das mal für alle, die nicht auf Anhieb verstehen wie geil dieser Deal ist. Der Deal-Partner betreibt Krankenhäuser in China. Man hat daher also direkt nach der Zulassung 6000 Krankenhäuser als Abnehmer. Es wird somit sehr bald nach der Zulassung direkt Umsatz generiert. |